Inhibitor of EZH2, 3-DZNep, was used to validate the function of EZH2 in vivo during AKI (Figure 7A), and SCr and BUN levels and kidney coefficients were decreased in the LPS+3-DZNep group, and pathological renal damage was alleviated (Figure 7B-D). This evidence concerns the gene EZH2 and acute kidney injury.